Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.

Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.

Item
http://www.wikidata.org/entity/Q34341948
Induction of tachykinin production in airway epithelia in response to viral infectionTreatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in miceSTAT4 deficiency fails to induce lung Th2 or Th17 immunity following primary or secondary respiratory syncytial virus (RSV) challenge but enhances the lung RSV-specific CD8+ T cell immune response to secondary challenge.Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease.The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance PAnti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV modelRespiratory syncytial virus--a comprehensive review.Substance P and the regulation of inflammation in infections and inflammatory bowel disease.Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins.The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis.Virokinin, a bioactive peptide of the tachykinin family, is released from the fusion protein of bovine respiratory syncytial virus.Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy.
P2860

Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.

Item
http://www.wikidata.org/entity/Q34341948
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Neutralizing anti-F glycoprote ...... ory syncytial virus infection.
@ast
Neutralizing anti-F glycoprote ...... ory syncytial virus infection.
@en
Neutralizing anti-F glycoprote ...... ory syncytial virus infection.
@nl
type
label
Neutralizing anti-F glycoprote ...... ory syncytial virus infection.
@ast
Neutralizing anti-F glycoprote ...... ory syncytial virus infection.
@en
Neutralizing anti-F glycoprote ...... ory syncytial virus infection.
@nl
prefLabel
Neutralizing anti-F glycoprote ...... ory syncytial virus infection.
@ast
Neutralizing anti-F glycoprote ...... ory syncytial virus infection.
@en
Neutralizing anti-F glycoprote ...... ory syncytial virus infection.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Neutralizing anti-F glycoprote ...... ory syncytial virus infection.
@en
P2093
P2860
P304
P31
P356
10.1128/JVI.76.14.6873-6881.2002
P407
P433
P478
P577
P5875
P698
P921
P932